White Blood Cell Growth Factors
Key Points
Key Points
Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.
Dose-dense regimens that require CSFs should be used only within an appropriately designed clinical trial or if supported by convincing efficacy data.
Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
Diagnosis
...Diagnosis...
...Patient Risk Factors for Febrile Neutropeni...
...Patient Risk Factors for Poor Clinical...
Treatment for Adult Patients
...Treatmen...
...mary prophylaxis with a CSF starting with the fir...
...ary prophylaxis with a CSF is reco...
...ould not be routinely used for patients with...
...ould not be routinely used as adjunc...
...breast cancer and lymphoma] ( EB , H , B , S )...
...lial cancer] ( EB , H , H , M )3336...
...Fs may be used alone, after chemot...
...e administered after autologous stem-cell tr...
...may be administered after allogeneic...
...ctic CSFs for patients with diffuse...
..., filgrastim, tbo-filgrastim, and filgrastim-sndz...
...mmendations for the management of patients expo...
Treatment for Pediatric Patients
...Treatmen...
...CSFs in pediatric patients will almost alwa...
For pediatric indications in which dose-in...
...should not be used in pediatric patients wit...
Table 3. Dosing and Administration of CSFs
Table 3. Dosing and Administration o...